QIAGEN OmicSoft and Biomedical Knowledge Base
Checkpoint inhibitor and immuno-oncology investigation leveraging curated high-quality public ‘omics data
15 views
While there is great interest in the scientific community to investigate drug targets and biomarkers from public immune-oncology data, such investigation is hindered by the difficulty in finding and combining related datasets to perform large-scale meta-analyses. This webinar will focus on how high-quality curated genomic repositories such as QIAGEN OmicSoft Lands immediately allows in-depth investigations across diverse data sources (GEO, CPTAC, TCGA, GTEx and more) to discover and validate candidate checkpoint inhibitor drug targets and biomarkers.
You will learn how to do the following in the graphical user interface and through APIs:
- Easily identify relevant samples using extensive manually curated clinical metadata
- Visualize and identify checkpoint inhibition biology related drug target and biomarkers expression patterns using expression data (RNA-seq, scRNA-seq, proteomics etc.)
- Reveal how the expression of a group of biomarkers (or genes/proteins of interest) correlates in normal and disease tissue
Related videos
QIAGEN OmicSoft and Biomedical Knowledge Base
Knowledge graphs and more: Analytics-driven drug discovery using advanced biomedical...
High-quality biomedical relationships knowledge is the cornerstone of modern...
QIAGEN OmicSoft and Biomedical Knowledge Base
Identify mutation hotspots in a gene of interest
In several cancers, IDH1 is frequently mutated at arginine 132, which alters...
QIAGEN OmicSoft and Biomedical Knowledge Base
Transcriptomics, Proteomics and Metabolic Changes in Post-Natal Mouse Heart analyzed with...
In the full talk, Jean-Noël Billaud, Ph.D. Senior Principal Scientist,...
QIAGEN OmicSoft and Biomedical Knowledge Base
Supercharge your AI in drug discovery with high-quality biomedical data
If you’re working in pharma or biotech, you likely rely on artificial...